# States and Substance Abuse Treatment Programs: Priorities, Guidelines and Funding for Infection-related Services

S. Kritz, MD; L.S. Brown, MD, MPH; R. J. Goldsmith, MD; E.J. Bini, MD, MPH; J. Robinson, MEd, D. Alderson, MS; J. Rotrosen, MD and the NIDA Clinical Trials Network Infections Study (CTN-0012) Team Addiction Research & Treatment Corp, Brooklyn, NY; University of Cincinnati Medical Center and VA Hospital, Cincinnati, OH; NYU School of Medicine and VA Hospital, NY, NY; Nathan Kline Institute, Orangeburg, NY; and NYS Psychiatric Institute, NY, NY

#### **ABSTRACT**

riorities, guidelines and funding availability. Program ors and clinicians were surveyed regarding clarity of guidelines strators were surveyed regarding clarity of guidelines strators were surveyed regarding funding availability for the lated services for the 3 infection groups.

: Surveys were received from 48 (96%) states and DC, 269 (84%) rators and 1723 (78%) clinicians. In states with guidelines for related services a significantly higher percent of program rators and clinicians indicated that treatment program guidelines ar. Although state agencies indicated that funding is widely available ion-related services, treatment program administrators were tly less aware of its availability. There was general agreement ates and between the departments within states regarding priorities, uidelines and funding availability.

**ACKNOWLEDGEMENTS** 

Research Supported by the National Institute on Drug

Abuse (NIDA) as part of a Cooperative Agreement

the NIDA Clinical Trials Network (CTN)

(1U10DA013046) between the Lead Node in NY and

Protocol team members and collaborators consisting

Randy Seewald, MD; Frank McCorry, PhD; Dennis McCarty,

PhD; Donald Calsyn, PhD; Steve Kipnis, MD; Leonard Handelsman, MD; Al Hassen, MSW; Shirley Irons; Karen

Reese, CAC-AD; Sherryl Baker, PhD; Kathlene Tracy, PhD

Node Protocol Managers, CTN Community Treatment

Programs (CTPs) and affiliated site administrators and

#### STUDY RATIONALE

- HIV/HCV/STI: major causes of excess morbidity and mortality in the US
- Substance abuse: a major vehicle for the transmission of these infections
- Scope of, and challenges to identifying, counseling, and treating persons with these infections in substance abuse treatment can assist in developing effective interventions
- Examine the interplay of substance abuse treatment programs with state and DC substance abuse and health departments

**DESIGN AND POPULATION** 

- Treatment Program Administrators

- Treatment Program Clinicians

**Abuse and Health Departments** 

#### **SELECTED SURVEY RESPONSES**

PRIMARY OBJECTIVES

**OF THIS REPORT** 

State and DC guidelines and clarity of program

Availability of funding as reported by state and

reported by treatment program administrators

funding for infection-related services in order

to determine generalizability of the findings

STATISTICAL MEASURES

For state and DC agencies vs. treatment programs:

Chi-square statistical associations between state and DC quidelines, as reported by state and DC administrators,

and "Clear" treatment program guidelines, as separately reported by treatment program administrators and

Chi-square statistical comparisons of priorities vs. funding

Chi-square statistical comparisons between jurisdictions

Chi-square statistical comparisons between substance abuse vs. health departments

Chi-square statistical associations for availability of

For state and DC agencies:

DC agencies vs. availability of funding as

• State and DC substance abuse and health

departments for priorities, guidelines and

TO EXAMINE ASSOCIATIONS BETWEEN:

Availability of funding (treatment program administrator and state surveys):

- Yes

Priorities (state survey):

- Not a priority
- Low priority Medium priority<sup>3</sup>
- High priority\*
- \* Response used for this report

#### Clarity of Treatment Program Guidelines in States with and without Written Guidelines for HIV Services: Program Administrator (n=269) and Clinician (n=1723) Perspectives

SERVICE	% of Administrators Reporting "Clear" Program Guidelines		% of Clinicians Reporting "Clear" Program Guidelines	
LIVICL	State Guidelines	No State Guidelines	State Guidelines	No State Guidelines
rovider Education	64*	44	59*	48
atient Education	68	50	63*	34
lisk Assessment	81*	57	68*	48
listory & Physical xamination	77	74	72*	60
esting	77	77	56*	47
ounseling	65	59	55	56
reatment	78*	61	64*	49
lonitoring	81*	62	61*	43

### Clarity of Treatment Program Guidelines in States with and Administrator (n=269) and Clinician (n=1723) Perspectives

	% of Administrators Reporting "Clear" Program Guidelines		% of Clinicians Reporting "Clear" Program Guidelines	
SERVICE	State Guidelines	No State Guidelines	State Guidelines	No State Guidelines
Provider Education	53*	39	48	44
Patient Education	56	61	51	52
Risk Assessment	71	64	55	51
History & Physical Examination	76	72	69*	57
Testing	70	69	40	49*
Counseling	58	50	47	48
Treatment	83*	60	57*	47
Monitoring	67	61	33	44*

#### Clarity of Treatment Program Guidelines in States with and without Written Guidelines for STI Services: Program Administrator (n=269) and Clinician (n=1723) Perspectives

% of Administrators Reporting "Clear" Program Guidelines		% of Clinicians Reporting "Clear" Program Guidelines	
State Guidelines	No State Guidelines	State Guidelines	No State Guidelines
51*	29	48*	37
57	49	52*	45
69*	50	57*	40
67	63	66*	56
70	67	45	43
52	49	48*	41
80*	57	57*	47
73*	52	51*	36
	"Clear" Progr 51* 57 69* 67 70 52 80*	**Clear" Program Guidelines  State Guidelines No State Guidelines  51* 29  57 49  69* 50  67 63  70 67  52 49  80* 57	"Clear" Program Guidelines         "Clear" Program Guidelines           State Guidelines         No State Guidelines           51*         29         48*           57         49         52*           69*         50         57*           67         63         66*           70         67         45           52         49         48*           80*         57         57*

#### **Percent of State and Treatment Program** Administrator "Yes" Responses to Availability of Funding for HIV Services (\* p≤0.05)

Service	State Response (%)	Program Response (%)
Provider Education	93*	60
Patient Education	100*	59
Patient Risk Assessment	98*	48
Patient Counseling	98*	60
Medical History & Exam	93*	54
Biological Testing	93*	65
Patient Treatment	96*	72
Patient Monitoring	93*	72

#### **Percent of State and Treatment Program** Administrator "Yes" Responses to Availability of Funding for HCV Services (\* p≤0.05)

Service	State Response (%)	Program Response (%)
ovider Education	62	61
ntient Education	71	61
ntient Risk Assessment	67*	48
ntient Counseling	80*	61
edical History & Exam	89*	50
ological Testing	71	60
atient Treatment	76	69
atient Monitoring	64	64

## **Percent of State and Treatment Program** Administrator "Yes" Responses to Availability

	9	· 1 _ /
Service	State Response (%)	Program Response (%)
Provider Education	87*	58
Patient Education	91*	60
Patient Risk Assessment	96*	62
Patient Counseling	98*	54
Medical History & Exam	96*	48
Biological Testing	93*	57
Patient Treatment	98*	66
Patient Monitoring	84*	59

#### **FINDINGS**

#### Comparing state and DC agencies across the country, there were:

• No statistically significant differences for 19 of 24 comparisons of priorities vs. funding (8 infection-related services for the 3 infection

\* Data not shown

#### **FINDINGS**

Comparing state and DC substance abuse and health departments, there were:

- No statistically significant differences for 45 of 48 comparisons of written guidelines and availability of funding (2 comparisons of the 8 infection-related services for the 3 infection
- \* Data not shown

#### CONCLUSIONS

Looking at state and DC agencies and the treatment programs within their jurisdiction, there was:

- Strongly positive association between presence of written state guidelines and "Clear" treatment program guidelines, as reported by both administrators and clinicians
- Little association between states and treatment programs in their respective responses regarding availability of funding

#### CONCLUSIONS

Looking at state and DC agencies, there was generalizability of the results:

- Between state and DC agencies across the US
- Between states with and without CTN treatment programs within their jurisdiction
- Between substance abuse and health departments

#### **FINDINGS**

Comparing state and DC agencies with CTN treatment programs vs. state and DC agencies without CTN programs, there were:

- No statistically significant differences for 66 of 72 comparisons of priorities, written guidelines and availability of funding (3 comparisons of the 8 infection-related services for the 3 infection groups)\*
- \* Data not shown

## **SUMMARY**

- Treatment program administrators and clinicians in jurisdictions with written guidelines for infection-related services were more likely to report their own program guidelines as "clear" when compared to jurisdictions without written guidelines
- Although state agencies indicated that funding is widely available for infection-related services, treatment program administrators were much less aware of its availability
- While states have established priorities, guidelines and funding, system complexity and challenges to accessing information may restrict availability of resources at the treatment program level

## **ACKNOWLEDGEMENTS**

- National Association of State Alcohol and Drug Abuse Directors (NASADAD)
- Association of State and Territorial Health Officials (ASTHO)
- National Alliance of State and Territorial AIDS Directors (NASTAD).
- There are no financial interests or disclosures to report for any of the authors involved in this project
- Drug Abuse Treatment Clinical Trials Network 17 Nodes with 116 Community Treatment Agencies Reaching into 26 States!



## **IMPORTANT TERMS**

Administrators of State and DC Substance

- 3 infection groups: HIV/AIDS, HCV, STI
- 8 infection-related services

STUDY DESIGN

Cross-sectional Survey

STUDY POPULATION

Descriptive & Exploratory

- Provider Education
- Patient Education
- Patient Risk Assessment
- Patient Counseling
- Patient Medical History & Physical Fxam
- Patient Biological Testing
- Patient Treatment
- CTN vs. non-CTN treatment programs
- State and DC substance abuse and health departments

## SELECTED SURVEY RESPONSES

Written regulations, policies or guidelines\* (state survey)

- Yes

\* Elsewhere referred to as Guidelines

Clarity of Treatment Program Guidelines (treatment program administrator and clinician surveys):

- Somewhat clear
- Don't know if guidelines exist
- No guidelines exist

# \* Response used for this report

## **FINDINGS**

- 269 administrators responded (84%) out of 319 substance abuse program administrators surveyed from 95 CTPs in the NIDA CTN, covering 25 states & DC
- 1723 clinicians of 2210 targeted (78%)
- At least one substance abuse or health department administrator from 48 states and DC (96%).